Creative Medical Technology comments on presidential initiative for IVF access

Creative Medical Technology (CELZ) stated that it supports President Trump’s executive order expanding access to in vitro fertilization, or IVF. This initiative directly aligns with the company’s vision to transform reproductive health through its groundbreaking OvaStem program, which has demonstrated an 85% improvement in hormonal function and a 70% success rate in delivering healthy babies using a patient’s own eggs-all with no safety concerns at up to five years post-treatment. The executive order signed February 18 mandates the Domestic Policy Council to deliver recommendations within 90 days to lower out-of-pocket IVF costs, which currently range from $12K to $25K per cycle. By removing these financial barriers, the administration’s plan paves the way for greater adoption of advanced fertility technologies.